Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Novo Nordisk

WeightWatchers Filing For Bankruptcy: Iconic Program Founded In 1963 Loses Clients To Ozempic And More

Founded in 1963, WeightWatchers faces bankruptcy with £1.25 billion ($1.6 billion) in debt, losing clients to drugs like Ozempic. Can the iconic programme survive?

International Business Times UK

EU drug companies warn of exodus to US as Trump threatens import tariffs

Von der Leyen urged to take ‘rapid and radical action’ as president says tariffs on pharmaceuticals coming ‘shortly’

The Guardian - UK

Europe’s pharma titans confront von der Leyen as Trump plans ’major’ tariffs

Novo Nordisk and Sanofi were among the companies threatening to hasten their exits to the U.S., as Trump promised pharma tariffs were coming “shortly.”

Fortune

From analysis to the latest developments in health,
read the most diverse news in one place.

Europe braces for Trump’s tariffs: What could the economic damage be?

Trump’s tariffs on EU goods could slash exports by at least €85 billion, hitting autos and pharmaceuticals hardest. Germany, Denmark and Central Europe face sharp fallout, raising recession risks and forcing the ECB to consider rate cuts.

Euronews

These 2 Mega-Cap Stocks Could Be Even Cheaper Buys Than Nvidia on the Dip

The market appears to be underestimating just how much these two companies can grow.

Barchart

Novo Nordisk shares post the biggest monthly decline since 2002

Novo Nordisk’s stocks experienced the sharpest monthly decline since July 2002 due to growing competition and several disappointing trial results. However, analysts remain optimistic about the shares, forecasting a potential price upside of up to 60% over the next 12 months.

Euronews

Tariff treatment: Six diagnoses for EU pharma sector amid US trade war

Potential US tariffs on pharmaceuticals could set off a ripple effect that extends far beyond the immediate price hikes, as both the US and Europe heavily rely on each other.

Euronews

Read news from The Economist, FT, and more,
with one subscription

How Diabetes Patients Are Fighting for Affordable Insulin

The World Health Organization states that there were around 830 million people living with diabetes in 2022. More than half of them weren't taking diabetes medications, including insulin, likely due to access and cost issues.

inkl

SAP has just become Europe's most valuable company, dethroning Novo Nordisk

The German software company's share price gained 40% in the past year, while Danish drugmaker Novo Nordisk has gradually lost almost half of its own since last summer.

Euronews

Cholet Agglo Tour: Lukáš Kubiš wins from the breakaway in rain-soaked round of the Coupe de France

The Slovakian rider outsprints Benjamin Thomas and Niklas Larsen for the victory in Cholet

Cycling News

Trump and Putin teased ‘enormous economic deals’ in their call—but U.S. companies will experience a very different Russia if they return

Russia has a new business elite and radically altered marketplace—and it’s done away with key legal protections.

Fortune

Katy Perry Flaunts Her Weight Loss After Addressing Ozempic Rumors: “She Looks Worse”

"The Ozempic face is crazy and her fillers are terrible" The post Katy Perry Flaunts Her Weight Loss After Addressing Ozempic Rumors: “She Looks Worse” first appeared on Bored Panda.

Bored Panda

Is Viking Therapeutics the Next Blockbuster GLP-1 Stock?

Viking Therapeutic may have a GLP-1 blockbuster on their hands with VK2735 as it produces weight loss at 5X the speed of Novo Nordisk's Wegovy GLP-1 drug.

MarketBeat

Ozempic can cost almost $2,000 a year. An Australian peak medical body says it should be on the PBS for weight loss

Research shows weight loss-inducing semaglutide medicines can help lower the risk of cardiovascular conditions and sleep apnea

The Guardian - AU

Get all your
news in one place.

100’s of premium titles.
One news app.

Barchart

Is Amgen Stock a Buy, Sell, or Hold as Weight-Loss Drug Trials Kick Off?

Amgen is hoping to rival Novo Nordisk and Eli Lilly in the weight-loss drug market.

Bored Panda

“Horrible Side Effects”: Experts Warn About Hollywood’s Ozempic Obsession

"Prioritize mental health." Hollywood’s “Ozempic craze” is worrying experts who believe it may be promoting harmful beauty standards. The post “Horrible Side Effects”: Experts Warn About Hollywood’s Ozempic Obsession first appeared on Bored Panda.

MarketBeat

Despite Challenges Novo Nordisk Plans to Crush GLP-1 Competitors

Novo Nordisk slashed prices on its GLP-1 obesity drugs as it launches NovoCare to gain compounded GLP-1 users as the compounding labs face deadlines to cease.

The Independent UK

How to eat well with diabetes – and save money doing it

Miguel Barclay has built a reputation on proving that good food doesn’t need to cost more than £1 a portion. Now, he’s created a collection of easy, affordable recipes designed for people with type 2 diabetes – meals that don’t just tick the nutritional boxes but taste good too, says…

Get all your
news in one place.

100’s of premium titles.
One news app.

Fortune

Novo Nordisk CEO warns tariffs could send the prices of Ozempic and Wegovy higher

Weight loss drugs are already taking a bite out of many people’s wallets.

The Independent UK

Novo Nordisk cuts Wegovy prices, following similar move by Zepbound-maker Eli Lilly

Makers of the popular obesity treatments Wegovy and Zepbound are cutting prices for people without insurance

The Independent UK

Weight-loss jab use rising among people with eating disorders, experts warn as NHS chief calls for crackdown

Online pharmacies and private providers have been urged to ‘act responsibly’ and ensure that the drugs are only prescribed to people with a medical need

Cycling Weekly

Class of 2025: Meet the 12 British cyclists who turned pro this year

A bounteous 12 Brits have stepped up to the pro ranks in 2025. Tom Davidson traces the skyward trajectories of a former runner, an adoptive Italian, and the WorldTour’s youngest rider

Barchart

Hims & Hers Stock Is Plunging on Weight-Loss Drug Halt. Should You Buy the Dip?

Concerns over near-term profit margins and the loss of potential revenue from compounded semaglutide weigh on Hims & Hers stock.

The Independent UK

Weight loss drugs linked to dozens of deaths

The medical director of the NHS has warned of the side effects of weight loss drugs after figures revealed the number of deaths associated with the jabs

MarketBeat

These 3 Stocks Just Announced Major Dividend Hikes

See which three stocks just raised their dividend payments by over 15%. On firm now has a sky-high indicated yield of over 10%.

1 … 11 12 13 14

People

Benjamin Thomas Cofidis

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.